Debt-to-equity of Grace Therapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Grace Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Dec 2020 to 31 Dec 2025.
Grace Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 7.4%, a 58% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Grace Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	7.4%	-10%	-58%	31 Dec 2025
Q3 2025	10%	-7.6%	-43%	30 Sep 2025
Q2 2025	13%	-5.2%	-29%	30 Jun 2025
Q1 2025	15%	-2.4%	-14%	31 Mar 2025
Q4 2024	18%	+1.1%	+7%	31 Dec 2024
Q3 2024	18%	+0.11%	+0.62%	30 Sep 2024
Q2 2024	18%	-0.78%	-4.2%	30 Jun 2024
Q1 2024	17%	-2.7%	-14%	31 Mar 2024
Q4 2023	16%	-3.6%	-18%	31 Dec 2023
Q3 2023	18%	+2.2%	+15%	30 Sep 2023
Q2 2023	19%	+7.2%	+64%	30 Jun 2023
Q1 2023	20%	+10%	+111%	31 Mar 2023
Q4 2022	20%	+13%	+196%	31 Dec 2022
Q3 2022	15%	+5.7%	+59%	30 Sep 2022
Q2 2022	11%	-4.9%	-30%	30 Jun 2022
Q1 2022	9.3%	-16%	-63%	31 Mar 2022
Q4 2021	6.7%	-42%	-86%	31 Dec 2021
Q3 2021	9.6%			30 Sep 2021
Q2 2021	16%			30 Jun 2021
Q1 2021	25%			31 Mar 2021
Q4 2020	49%			31 Dec 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.